Radiogenomics: a key component of precision cancer medicine

Radiogenomics, focusing on the relationship between genomics and imaging phenotypes, has been widely applied to address tumour heterogeneity and predict immune responsiveness and progression. It is an inevitable consequence of current trends in precision medicine, as radiogenomics costs less than traditional genetic sequencing and provides access to whole-tumour information rather than limited biopsy specimens. By providing voxel-by-voxel genetic information, radiogenomics can allow tailored therapy targeting a complete, heterogeneous tumour or set of tumours. In addition to quantifying lesion characteristics, radiogenomics can also be used to distinguish benign from malignant entities, as well as patient characteristics, to better stratify patients according to disease risk, thereby enabling more precise imaging and screening. Here, we have characterised the radiogenomic application in precision medicine using a multi-omic approach. we outline the main applications of radiogenomics in diagnosis, treatment planning and evaluations in the field of oncology with the aim of developing quantitative and personalised medicine. Finally, we discuss the challenges in the field of radiogenomics and the scope and clinical applicability of these methods.

Automated summary

Radiogenomics, a field that explores the relationship between genomics and imaging phenotypes, has been widely used to address tumor heterogeneity, predict immune response and progression. It offers a lower-cost alternative to traditional genetic sequencing and provides access to whole-tumor information. By providing voxel-by-voxel genetic information, radiogenomics enables tailored therapy for heterogeneous tumors and better stratifies patients for more precise imaging and screening.